The Axone 4LV lead is currently subject to a clinical evaluation and is not commercially available.
REFERENCES
[1] Brignole M et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2281–2329.
[2] Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
[3] Daubert JC et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure. Europace. 2012;14:1236-1286.
[4] Khan FZ, Virdee MS, Palmer CR, et al. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol 2012;59:1509-1518.